Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Other Long-Term Liabilities : €11.1 Mil (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co Other Long-Term Liabilities?

Biocytogen Pharmaceuticals (Beijing) Co's other long-term liabilities for the quarter that ended in Dec. 2024 was €11.1 Mil.

Biocytogen Pharmaceuticals (Beijing) Co's quarterly other long-term liabilities declined from Dec. 2023 (€11.4 Mil) to Jun. 2024 (€11.2 Mil) and declined from Jun. 2024 (€11.2 Mil) to Dec. 2024 (€11.1 Mil).

Biocytogen Pharmaceuticals (Beijing) Co's annual other long-term liabilities declined from Dec. 2022 (€12.2 Mil) to Dec. 2023 (€11.4 Mil) and declined from Dec. 2023 (€11.4 Mil) to Dec. 2024 (€11.1 Mil).

Biocytogen Pharmaceuticals (Beijing) Co Other Long-Term Liabilities Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co Other Long-Term Liabilities Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Other Long-Term Liabilities

11.33

12.89

12.18

11.43

11.14

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Other Long-Term Liabilities	Get a 7-Day Free Trial				12.18	11.41	11.43	11.16	11.14

Biocytogen Pharmaceuticals (Beijing) Co Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Biocytogen Pharmaceuticals (Beijing) Co Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocytogen Pharmaceuticals (Beijing) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (FRA:I54) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

02315:Hong Kong

Address

12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN

Website

https://www.biocytogen.com.cn

Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.

Biocytogen Pharmaceuticals (Beijing) Co Headlines

No Headlines